Trending tickers: Tesla, ABF, Novartis, Taylor Wimpey, JD Sports
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2024
0mins
Source: Yahoo Finance
- Tesla Earnings Report: Tesla is set to report its first-quarter earnings, with expectations of a revenue decline and a 40% slide in operating profit compared to last year.
- Tesla Price Cuts: Tesla cut prices of its EV models in the US and globally, including China, to boost demand for its vehicles.
- ABF Financial Results: Associated British Foods (ABF) reported a 39% jump in earnings in the first half of the financial year, driven by new store openings and price increases at Primark.
- Novartis Performance: Novartis raised its full-year guidance after better-than-expected first-quarter results, with net sales up 11% and core operating income increasing by 22%.
- Taylor Wimpey Update: Taylor Wimpey reiterated its guidance for 2024 and saw a rise in sales rate during the spring selling season, aiming to build around 9,500 to 10,000 homes in Britain this year.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 127.75 USD with a low forecast of 112.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 145.000
Low
112.00
Averages
127.75
High
143.00
Current: 145.000
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
